社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
458b6d98
hi
IP属地：未知
+关注
帖子 · 222
帖子 · 222
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
458b6d98
458b6d98
·
2021-12-27
Ok
非常抱歉，此主贴已删除
看
3,618
回复
评论
点赞
4
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-12-24
Mehhh
Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>
The Covid-19 pill is here, and it couldn’t have come at a better time. The pandemic grew darker over
Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>
看
2,567
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-12-20
Diei
非常抱歉，此主贴已删除
看
2,629
回复
1
点赞
4
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-12-11
Kk
非常抱歉，此主贴已删除
看
3,302
回复
1
点赞
4
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-12-06
Lab
Lucid stock plunged 16% in premarket trading<blockquote>Lucid股价在盘前交易中暴跌16%</blockquote>
Lucid stock plunged 16% in premarket trading after the electric car maker received subpoena from U.S
Lucid stock plunged 16% in premarket trading<blockquote>Lucid股价在盘前交易中暴跌16%</blockquote>
看
2,679
回复
评论
点赞
6
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-12-03
Maybe
'The bond market is not yet prepared' -- here's what a Wall Street veteran fears<blockquote>“债券市场尚未准备好”——这是一位华尔街资深人士的担忧</blockquote>
As the signals from the Federal Reserve become louder and louder that interest rates will be hiked n
'The bond market is not yet prepared' -- here's what a Wall Street veteran fears<blockquote>“债券市场尚未准备好”——这是一位华尔街资深人士的担忧</blockquote>
看
2,735
回复
1
点赞
3
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-11-28
Gulah
@小左第一视角：
美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五
美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五
看
2,444
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-11-26
Knn
非常抱歉，此主贴已删除
看
2,440
回复
评论
点赞
1
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-11-13
Good
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
看
2,797
回复
1
点赞
6
编组 21备份 2
分享
举报
458b6d98
458b6d98
·
2021-11-03
Kk
Activision Blizzard stock dropped 11% in premarket trading<blockquote>动视暴雪股价盘前交易下跌11%</blockquote>
Activision Blizzard Inc. shares sank in premarket trading Wednesday after the videogame publisher’s
Activision Blizzard stock dropped 11% in premarket trading<blockquote>动视暴雪股价盘前交易下跌11%</blockquote>
看
2,785
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3556756933727652","uuid":"3556756933727652","gmtCreate":1593662911398,"gmtModify":1612937277545,"name":"458b6d98","pinyin":"nicsim","introduction":"","introductionEn":"","signature":"hi","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":247,"headSize":9,"tweetSize":222,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696041859,"gmtCreate":1640583944330,"gmtModify":1640583946639,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696041859","repostId":"1174372651","repostType":4,"isVote":1,"tweetType":1,"viewCount":3618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698109374,"gmtCreate":1640312308524,"gmtModify":1640313673855,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Mehhh","listText":"Mehhh","text":"Mehhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698109374","repostId":"1110395878","repostType":4,"repost":{"id":"1110395878","kind":"news","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=zh_CN&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p><p><blockquote>新冠肺炎药丸来了，来得正是时候。</blockquote></p><p> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p><p><blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法因该变种的突变而变得无用，病例数迅速攀升，医生和公共卫生官员越来越担心。</blockquote></p><p> The Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p><p><blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的Covid-19药物Paxlovid带来了一些希望。这种药丸仅适用于高危人群，最初供应有限，但它将拯救生命。</blockquote></p><p> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p><p><blockquote>此次授权对辉瑞来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二次授权。FactSet的数据显示，分析师预计辉瑞公司将在2022年销售价值217亿美元的该药物，不过该公司现在表示明年将生产1.2亿个疗程的该药物，比之前的预测多4000万个疗程，这可能会推高这些估计。</blockquote></p><p> As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p><p><blockquote>作为<i>巴伦周刊</i>去年11月，Paxlovid的成功进一步证明，该公司在2019年决定摆脱除创新生物制药业务以外的所有业务是明智的。</blockquote></p><p> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.</p><p><blockquote>投资者一直迟迟没有买入重组后的辉瑞，但今年年底他们很快就赶上了。在今年11月之前的12个月里，辉瑞的股价落后于标准普尔500指数，尽管它推出了新冠肺炎疫苗。然而，自11月初以来，辉瑞股价大幅上涨。此后，该股上涨了36.4%，而标普500仅上涨了1.6%。</blockquote></p><p> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.</p><p><blockquote>FactSet的数据显示，该股仍然相对便宜，未来12个月预期市盈率仅为9.8倍，低于礼来公司(LLY)和强生公司(JNJ)等同行，市盈率为31.7倍。市盈率为16.1倍。</blockquote></p><p> The good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p><p><blockquote>本周辉瑞的好消息与默克（MRK）的坏消息相匹配。尽管其Covid-19药物molnupiravir的早期数据导致疫苗股走低，默克公司股价走高，但此后该药物的光芒已经消失，因为更新的数据表明它的效果不如最初看起来的那么好，而且安全问题仍然存在。</blockquote></p><p> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p><p><blockquote>FDA于周四发布了molnupiravir的紧急使用授权，一天前它发布了Paxlovid的紧急使用授权，但条款要严格得多。该授权允许molnupiravir仅在其他Covid-19治疗方法（如Paxlovid）不可用或临床不合适时使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹韦的男性在怀孕后至少三个月内应采取避孕措施。</blockquote></p><p> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p><p><blockquote>早些时候对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：失去Keytruda的专利保护，Keytruda是一种癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞的Covid药丸获得批准。投资者开始关注该股。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-24 09:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p><p><blockquote>新冠肺炎药丸来了，来得正是时候。</blockquote></p><p> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p><p><blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法因该变种的突变而变得无用，病例数迅速攀升，医生和公共卫生官员越来越担心。</blockquote></p><p> The Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p><p><blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的Covid-19药物Paxlovid带来了一些希望。这种药丸仅适用于高危人群，最初供应有限，但它将拯救生命。</blockquote></p><p> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p><p><blockquote>此次授权对辉瑞来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二次授权。FactSet的数据显示，分析师预计辉瑞公司将在2022年销售价值217亿美元的该药物，不过该公司现在表示明年将生产1.2亿个疗程的该药物，比之前的预测多4000万个疗程，这可能会推高这些估计。</blockquote></p><p> As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p><p><blockquote>作为<i>巴伦周刊</i>去年11月，Paxlovid的成功进一步证明，该公司在2019年决定摆脱除创新生物制药业务以外的所有业务是明智的。</blockquote></p><p> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.</p><p><blockquote>投资者一直迟迟没有买入重组后的辉瑞，但今年年底他们很快就赶上了。在今年11月之前的12个月里，辉瑞的股价落后于标准普尔500指数，尽管它推出了新冠肺炎疫苗。然而，自11月初以来，辉瑞股价大幅上涨。此后，该股上涨了36.4%，而标普500仅上涨了1.6%。</blockquote></p><p> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.</p><p><blockquote>FactSet的数据显示，该股仍然相对便宜，未来12个月预期市盈率仅为9.8倍，低于礼来公司(LLY)和强生公司(JNJ)等同行，市盈率为31.7倍。市盈率为16.1倍。</blockquote></p><p> The good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p><p><blockquote>本周辉瑞的好消息与默克（MRK）的坏消息相匹配。尽管其Covid-19药物molnupiravir的早期数据导致疫苗股走低，默克公司股价走高，但此后该药物的光芒已经消失，因为更新的数据表明它的效果不如最初看起来的那么好，而且安全问题仍然存在。</blockquote></p><p> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p><p><blockquote>FDA于周四发布了molnupiravir的紧急使用授权，一天前它发布了Paxlovid的紧急使用授权，但条款要严格得多。该授权允许molnupiravir仅在其他Covid-19治疗方法（如Paxlovid）不可用或临床不合适时使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹韦的男性在怀孕后至少三个月内应采取避孕措施。</blockquote></p><p> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p><p><blockquote>早些时候对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：失去Keytruda的专利保护，Keytruda是一种癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693322153,"gmtCreate":1639974369680,"gmtModify":1639974371978,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Diei","listText":"Diei","text":"Diei","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693322153","repostId":"1135122268","repostType":4,"isVote":1,"tweetType":1,"viewCount":2629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605705810,"gmtCreate":1639238025765,"gmtModify":1639238027906,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Kk","listText":"Kk","text":"Kk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605705810","repostId":"2190620320","repostType":4,"isVote":1,"tweetType":1,"viewCount":3302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608785255,"gmtCreate":1638791076022,"gmtModify":1638791509598,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Lab","listText":"Lab","text":"Lab","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608785255","repostId":"1169549915","repostType":4,"repost":{"id":"1169549915","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638790330,"share":"https://www.laohu8.com/m/news/1169549915?lang=zh_CN&edition=full","pubTime":"2021-12-06 19:32","market":"us","language":"en","title":"Lucid stock plunged 16% in premarket trading<blockquote>Lucid股价在盘前交易中暴跌16%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169549915","media":"Tiger Newspress","summary":"Lucid stock plunged 16% in premarket trading after the electric car maker received subpoena from U.S","content":"<p>Lucid stock plunged 16% in premarket trading after the electric car maker received subpoena from U.S. SEC.</p><p><blockquote>电动汽车制造商Lucid收到美国SEC的传票后，该公司股价在盘前交易中暴跌16%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5dfa0d73ad31c40158f7d7142b2f6069\" tg-width=\"851\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Lucid Group Inc has received a subpoena from the U.S. Securities and Exchange Commission seeking documents related to a probe on its blank-check deal, the Luxury electric-car maker said on Monday.</p><p><blockquote>豪华电动汽车制造商Lucid Group Inc周一表示，已收到美国证券交易委员会的传票，要求提供与其空白支票交易调查相关的文件。</blockquote></p><p> \"The investigation appears to concern the business combination between the Company (Churchill Capital Corp. IV) and Atieva Inc and certain projections and statements,\" the company said in a regulatory filing.</p><p><blockquote>该公司在一份监管文件中表示：“调查似乎涉及该公司（Churchill Capital Corp.IV）和Atieva Inc之间的业务合并以及某些预测和声明。”</blockquote></p><p> The deal, which was completed earlier this year, was with veteran dealmaker Michael Klein's blank-check acquisition firm.</p><p><blockquote>该交易于今年早些时候完成，是与资深交易撮合者迈克尔·克莱因(Michael Klein)的空白支票收购公司进行的。</blockquote></p><p> It was one of the biggest in a string of deals by electric vehicle makers such as Nikola Corp and Fisker Inc that have gone public by combining with special purpose acquisition companies (SPACs).</p><p><blockquote>这是尼古拉公司(Nikola Corp)和菲斯克公司(Fisker Inc)等电动汽车制造商通过与特殊目的收购公司(SPAC)合并上市的一系列交易中最大的一笔。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid stock plunged 16% in premarket trading<blockquote>Lucid股价在盘前交易中暴跌16%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid stock plunged 16% in premarket trading<blockquote>Lucid股价在盘前交易中暴跌16%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-06 19:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Lucid stock plunged 16% in premarket trading after the electric car maker received subpoena from U.S. SEC.</p><p><blockquote>电动汽车制造商Lucid收到美国SEC的传票后，该公司股价在盘前交易中暴跌16%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5dfa0d73ad31c40158f7d7142b2f6069\" tg-width=\"851\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Lucid Group Inc has received a subpoena from the U.S. Securities and Exchange Commission seeking documents related to a probe on its blank-check deal, the Luxury electric-car maker said on Monday.</p><p><blockquote>豪华电动汽车制造商Lucid Group Inc周一表示，已收到美国证券交易委员会的传票，要求提供与其空白支票交易调查相关的文件。</blockquote></p><p> \"The investigation appears to concern the business combination between the Company (Churchill Capital Corp. IV) and Atieva Inc and certain projections and statements,\" the company said in a regulatory filing.</p><p><blockquote>该公司在一份监管文件中表示：“调查似乎涉及该公司（Churchill Capital Corp.IV）和Atieva Inc之间的业务合并以及某些预测和声明。”</blockquote></p><p> The deal, which was completed earlier this year, was with veteran dealmaker Michael Klein's blank-check acquisition firm.</p><p><blockquote>该交易于今年早些时候完成，是与资深交易撮合者迈克尔·克莱因(Michael Klein)的空白支票收购公司进行的。</blockquote></p><p> It was one of the biggest in a string of deals by electric vehicle makers such as Nikola Corp and Fisker Inc that have gone public by combining with special purpose acquisition companies (SPACs).</p><p><blockquote>这是尼古拉公司(Nikola Corp)和菲斯克公司(Fisker Inc)等电动汽车制造商通过与特殊目的收购公司(SPAC)合并上市的一系列交易中最大的一笔。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169549915","content_text":"Lucid stock plunged 16% in premarket trading after the electric car maker received subpoena from U.S. SEC.\n\nLucid Group Inc has received a subpoena from the U.S. Securities and Exchange Commission seeking documents related to a probe on its blank-check deal, the Luxury electric-car maker said on Monday.\n\"The investigation appears to concern the business combination between the Company (Churchill Capital Corp. IV) and Atieva Inc and certain projections and statements,\" the company said in a regulatory filing.\nThe deal, which was completed earlier this year, was with veteran dealmaker Michael Klein's blank-check acquisition firm.\nIt was one of the biggest in a string of deals by electric vehicle makers such as Nikola Corp and Fisker Inc that have gone public by combining with special purpose acquisition companies (SPACs).","news_type":1,"symbols_score_info":{"LCID":0.9}},"isVote":1,"tweetType":1,"viewCount":2679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601270623,"gmtCreate":1638539863365,"gmtModify":1638539864278,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Maybe","listText":"Maybe","text":"Maybe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601270623","repostId":"2188854525","repostType":4,"repost":{"id":"2188854525","kind":"highlight","pubTimestamp":1638536261,"share":"https://www.laohu8.com/m/news/2188854525?lang=zh_CN&edition=full","pubTime":"2021-12-03 20:57","market":"us","language":"en","title":"'The bond market is not yet prepared' -- here's what a Wall Street veteran fears<blockquote>“债券市场尚未准备好”——这是一位华尔街资深人士的担忧</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2188854525","media":"MarketWatch","summary":"As the signals from the Federal Reserve become louder and louder that interest rates will be hiked n","content":"<p>As the signals from the Federal Reserve become louder and louder that interest rates will be hiked next year, the question for markets becomes less about when and more about, how high.</p><p><blockquote>随着美联储明年加息的信号越来越大，市场面临的问题不再是何时加息，而是加息幅度有多大。</blockquote></p><p> Nearly every rate-hike cycle since the 1970s has resulted in successively lower peaks. That's logical, because inflation also has had lower peaks.</p><p><blockquote>自20世纪70年代以来，几乎每个加息周期都会导致峰值不断降低。这是合乎逻辑的，因为通胀峰值也较低。</blockquote></p><p> \"In essence, a secular decline in inflation has mitigated the need for monetary policy makers to lift official interest rates as much as previous business cycles,\" said Joe LaVorgna, the chief economist of the Americas for Natixis Corporate and Investment Banking, who also was chief economist for the White House National Economic Council in the latter days of the Trump administration.</p><p><blockquote>Natixis企业和投资银行美洲首席经济学家Joe LaVorgna表示：“从本质上讲，通胀的长期下降减轻了货币政策制定者像之前商业周期那样提高官方利率的需要。”特朗普政府后期担任白宫国家经济委员会首席经济学家。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/766e2ce17be0292d43f5fd3a83ce848a\" tg-width=\"700\" tg-height=\"505\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Markets have learned. Measured by five-year overnight index swaps, traders expect the next rate hike cycle to peak at just 1.45%. And adjusted for inflation, real rates are forecast not to get into positive territory in this business cycle.</p><p><blockquote>市场已经吸取了教训。以五年期隔夜指数掉期衡量，交易员预计下一个加息周期的峰值仅为1.45%。经通胀调整后，预计实际利率在本商业周期中不会进入正值区域。</blockquote></p><p> LaVorgna said markets may be in store for a rude awakening. \"But unprecedented fiscal and monetary stimulus since COVID may have reversed the post-1980s secular downtrend in inflation. If this is the case, then the real fed-funds rate eventually needs to get back into positive territory to dampen inflationary pressure,\" he said.</p><p><blockquote>LaVorgna表示，市场可能会猛然醒悟。“但自新冠疫情以来前所未有的财政和货币刺激措施可能扭转了20世纪80年代后通胀的长期下降趋势。如果是这样的话，那么实际联邦基金利率最终需要回到正值区域，以抑制通胀压力，”他说。</blockquote></p><p> LaVorgna said the bond market isn't yet prepared. And to MarketWatch, he said neither is the stock market. The end result for equities? \"Eventually a serious compression in multiples,\" he said in an email. The last reading for the Shiller price-to-equty ratio was a staggering 39.</p><p><blockquote>拉沃尼亚表示，债券市场尚未做好准备。他对MarketWatch表示，股市也不是。股票的最终结果？“最终倍数会严重压缩，”他在一封电子邮件中说。席勒市盈率的最新读数是惊人的39。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>'The bond market is not yet prepared' -- here's what a Wall Street veteran fears<blockquote>“债券市场尚未准备好”——这是一位华尔街资深人士的担忧</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n'The bond market is not yet prepared' -- here's what a Wall Street veteran fears<blockquote>“债券市场尚未准备好”——这是一位华尔街资深人士的担忧</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-12-03 20:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>As the signals from the Federal Reserve become louder and louder that interest rates will be hiked next year, the question for markets becomes less about when and more about, how high.</p><p><blockquote>随着美联储明年加息的信号越来越大，市场面临的问题不再是何时加息，而是加息幅度有多大。</blockquote></p><p> Nearly every rate-hike cycle since the 1970s has resulted in successively lower peaks. That's logical, because inflation also has had lower peaks.</p><p><blockquote>自20世纪70年代以来，几乎每个加息周期都会导致峰值不断降低。这是合乎逻辑的，因为通胀峰值也较低。</blockquote></p><p> \"In essence, a secular decline in inflation has mitigated the need for monetary policy makers to lift official interest rates as much as previous business cycles,\" said Joe LaVorgna, the chief economist of the Americas for Natixis Corporate and Investment Banking, who also was chief economist for the White House National Economic Council in the latter days of the Trump administration.</p><p><blockquote>Natixis企业和投资银行美洲首席经济学家Joe LaVorgna表示：“从本质上讲，通胀的长期下降减轻了货币政策制定者像之前商业周期那样提高官方利率的需要。”特朗普政府后期担任白宫国家经济委员会首席经济学家。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/766e2ce17be0292d43f5fd3a83ce848a\" tg-width=\"700\" tg-height=\"505\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Markets have learned. Measured by five-year overnight index swaps, traders expect the next rate hike cycle to peak at just 1.45%. And adjusted for inflation, real rates are forecast not to get into positive territory in this business cycle.</p><p><blockquote>市场已经吸取了教训。以五年期隔夜指数掉期衡量，交易员预计下一个加息周期的峰值仅为1.45%。经通胀调整后，预计实际利率在本商业周期中不会进入正值区域。</blockquote></p><p> LaVorgna said markets may be in store for a rude awakening. \"But unprecedented fiscal and monetary stimulus since COVID may have reversed the post-1980s secular downtrend in inflation. If this is the case, then the real fed-funds rate eventually needs to get back into positive territory to dampen inflationary pressure,\" he said.</p><p><blockquote>LaVorgna表示，市场可能会猛然醒悟。“但自新冠疫情以来前所未有的财政和货币刺激措施可能扭转了20世纪80年代后通胀的长期下降趋势。如果是这样的话，那么实际联邦基金利率最终需要回到正值区域，以抑制通胀压力，”他说。</blockquote></p><p> LaVorgna said the bond market isn't yet prepared. And to MarketWatch, he said neither is the stock market. The end result for equities? \"Eventually a serious compression in multiples,\" he said in an email. The last reading for the Shiller price-to-equty ratio was a staggering 39.</p><p><blockquote>拉沃尼亚表示，债券市场尚未做好准备。他对MarketWatch表示，股市也不是。股票的最终结果？“最终倍数会严重压缩，”他在一封电子邮件中说。席勒市盈率的最新读数是惊人的39。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/the-bond-market-is-not-yet-prepared-heres-what-a-wall-street-veteran-fears-11638532504?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","BK4022":"陆运","BK4528":"SaaS概念","BK4505":"高瓴资本持仓","BK4079":"房地产服务","BK4535":"淡马锡持仓","BK4515":"5G概念",".SPX":"S&P 500 Index","Z":"Zillow","BK4548":"巴美列捷福持仓","BK4112":"金融交易所和数据","MRVL":"迈威尔科技","ZG":"Zillow Class A","ICE":"洲际交易所","BK4551":"寇图资本持仓",".DJI":"道琼斯","BK4561":"索罗斯持仓","BK4539":"次新股","BK4023":"应用软件","BK4526":"热门中概股","BK4141":"半导体产品"},"source_url":"https://www.marketwatch.com/story/the-bond-market-is-not-yet-prepared-heres-what-a-wall-street-veteran-fears-11638532504?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188854525","content_text":"As the signals from the Federal Reserve become louder and louder that interest rates will be hiked next year, the question for markets becomes less about when and more about, how high.\nNearly every rate-hike cycle since the 1970s has resulted in successively lower peaks. That's logical, because inflation also has had lower peaks.\n\"In essence, a secular decline in inflation has mitigated the need for monetary policy makers to lift official interest rates as much as previous business cycles,\" said Joe LaVorgna, the chief economist of the Americas for Natixis Corporate and Investment Banking, who also was chief economist for the White House National Economic Council in the latter days of the Trump administration.\n\nMarkets have learned. Measured by five-year overnight index swaps, traders expect the next rate hike cycle to peak at just 1.45%. And adjusted for inflation, real rates are forecast not to get into positive territory in this business cycle.\nLaVorgna said markets may be in store for a rude awakening. \"But unprecedented fiscal and monetary stimulus since COVID may have reversed the post-1980s secular downtrend in inflation. If this is the case, then the real fed-funds rate eventually needs to get back into positive territory to dampen inflationary pressure,\" he said.\nLaVorgna said the bond market isn't yet prepared. And to MarketWatch, he said neither is the stock market. The end result for equities? \"Eventually a serious compression in multiples,\" he said in an email. The last reading for the Shiller price-to-equty ratio was a staggering 39.","news_type":1,"symbols_score_info":{".IXIC":0.9,"ZG":0.9,"ICE":0.9,".DJI":0.9,".SPX":0.9,"MRVL":0.9,"Z":0.9}},"isVote":1,"tweetType":1,"viewCount":2735,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600899599,"gmtCreate":1638112337211,"gmtModify":1638112338144,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Gulah","listText":"Gulah","text":"Gulah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600899599","repostId":"877290040","repostType":1,"repost":{"id":877290040,"gmtCreate":1637932396277,"gmtModify":1637935514436,"author":{"id":"9000000000000104","authorId":"9000000000000104","name":"小左第一视角","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000104","idStr":"9000000000000104"},"themes":[],"title":"","htmlText":"\n \n \n 美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五\n \n","listText":"美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五","text":"美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877290040","isVote":1,"tweetType":2,"object":{"id":"538f864f8bc94efea8814f5f969bec2d","tweetId":"877290040","title":"美股股指大暴跌，怎么办？这只股票盘前竟涨了，抄底准备中。AAPL、AFRM、AMAT、BABA、BB、CRM、DIS、LCID、NIO、NVDA、PLTR、TSLA、ROKU小左1126五","videoUrl":"http://v.tigerbbs.com/163793239316012b94d46af116c97672f6839812135ad.mp4","poster":"https://static.tigerbbs.com/37bbf57f4cb62133c38147f8856c7cc8","shareLink":"http://v.tigerbbs.com/163793239316012b94d46af116c97672f6839812135ad.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877376940,"gmtCreate":1637892804703,"gmtModify":1637892805612,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Knn","listText":"Knn","text":"Knn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877376940","repostId":"2186937803","repostType":4,"isVote":1,"tweetType":1,"viewCount":2440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873017236,"gmtCreate":1636796776238,"gmtModify":1636796777048,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873017236","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841558475,"gmtCreate":1635927958094,"gmtModify":1635927958878,"author":{"id":"3556756933727652","authorId":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3556756933727652","idStr":"3556756933727652"},"themes":[],"htmlText":"Kk","listText":"Kk","text":"Kk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841558475","repostId":"1123197935","repostType":4,"repost":{"id":"1123197935","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635926581,"share":"https://www.laohu8.com/m/news/1123197935?lang=zh_CN&edition=full","pubTime":"2021-11-03 16:03","market":"us","language":"en","title":"Activision Blizzard stock dropped 11% in premarket trading<blockquote>动视暴雪股价盘前交易下跌11%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123197935","media":"Tiger Newspress","summary":"Activision Blizzard Inc. shares sank in premarket trading Wednesday after the videogame publisher’s ","content":"<p>Activision Blizzard Inc. shares sank in premarket trading Wednesday after the videogame publisher’s lighter-than-expected outlook and expected delay of two games eclipsed an earnings beat and commitments to a safe and equitable work environment.</p><p><blockquote>动视暴雪公司(Activision Blizzard Inc.)股价周三在盘前交易中下跌，此前这家视频游戏发行商的前景弱于预期，两款游戏的预期延迟盖过了盈利预期以及对安全公平工作环境的承诺。</blockquote></p><p> Activision Blizzard shares sank more than 11% after the earnings call. Shares fell 2.1% to close at $77.67 Tuesday to give Activision Blizzard a $60.4 billion market cap.</p><p><blockquote>财报看涨期权公布后，动视暴雪股价下跌逾11%。周二，动视暴雪股价下跌2.1%，收于77.67美元，市值达到604亿美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/75c797cd99fe04a5d5f5968df8835903\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The company said it expects fourth-quarter adjusted earnings of 62 cents a share on revenue of $2.02 billion and bookings of $2.78 billion. The company also raised its full-year forecast to earnings of $3.70 a share on revenue of $8.66 billion and bookings of $8.65 billion, compared with its quarter-ago forecast of $3.54 a share on revenue of $8.52 billion and bookings of $8.65 billion for the year.</p><p><blockquote>该公司表示，预计第四季度调整后每股收益为62美分，营收为20.2亿美元，预订量为27.8亿美元。该公司还将全年预期上调至每股收益3.70美元，营收86.6亿美元，预订量86.5亿美元，而上一季度预期为每股收益3.54美元，全年营收85.2亿美元，预订量86.5亿美元。</blockquote></p><p> Analysts, however, estimated earnings of $1.38 a share on revenue of $2.91 billion and bookings of $2.89 billion for the fourth quarter, and earnings of $3.83 a share on revenue of $8.79 billion and bookings of $8.76 billion for the year.</p><p><blockquote>然而，分析师预计第四季度每股收益为1.38美元，营收为29.1亿美元，预订量为28.9亿美元，全年每股收益为3.83美元，营收为87.9亿美元，预订量为87.6亿美元。</blockquote></p><p> Activision Blizzard Chief Financial Officer Armin Zerza said on the call “we remain prudent in our revenue assumption for the fourth quarter, and regarding costs we have decided to further step up investment in mobile marketing given the strong returns we are currently seeing and compliance in the organization.”</p><p><blockquote>动视暴雪首席财务官Armin Zerza在看涨期权上表示：“我们对第四季度的收入假设保持谨慎，在成本方面，鉴于我们目前看到的强劲回报和合规性，我们决定进一步加大对移动营销的投资在组织中。”</blockquote></p><p> For the fourth quarter, Activision Blizzard said it will roll out “Call of Duty: Vanguard” on Friday, and the franchise’s “Warzone Pacific” update on Dec. 5. Other anticipated titles, however, are getting delayed.</p><p><blockquote>对于第四季度，动视暴雪表示将于周五推出《使命看涨期权：先锋》，并于12月5日推出该系列的《战区太平洋》更新。然而，其他预期的标题正在被推迟。</blockquote></p><p> “While we are still planning to deliver a substantial amount of content from Blizzard next year, we are now planning for a later launch for ‘Overwatch 2’ and ‘Diablo IV’ than originally envisaged,” Daniel Alegre, the company’s chief operating officer, said on the call. “These are two of the most eagerly anticipated titles in the industry, and our teams have made great strides towards completion in recent quarters.”</p><p><blockquote>该公司首席运营官Daniel Alegre在看涨期权上表示：“虽然我们仍计划明年从暴雪提供大量内容，但我们现在计划推出《守望先锋2》和《暗黑破坏神4》的时间比最初设想的要晚。”“这是业内最受期待的两个游戏，我们的团队最近几个季度在完成方面取得了长足的进步。”</blockquote></p><p> Delays in releases have become more commonplace as publishers seek to avoid releasing games that may still have bugs, especially since CD Projekt SA’s long-awaited and long-overdue release last year of “Cyberpunk 2077” that forced distributors like Sony Group Corp. to offer full refunds.</p><p><blockquote>随着发行商试图避免发布可能仍有漏洞的游戏，发行延迟变得越来越普遍，特别是自CD Projekt SA去年发布期待已久的《赛博朋克2077》以来，该游戏迫使索尼集团公司等发行商提供全额退款。</blockquote></p><p> The company reported third-quarter net income of $639 million, or 82 cents a share, compared with $604 million, or 78 cents a share, in the year-ago period. Activision said adjusted earnings, which exclude share-based compensation expenses and other items, rose 89 cents a share from 88 cents a share in the year-ago period.</p><p><blockquote>该公司报告第三季度净利润为6.39亿美元，即每股82美分，而去年同期为6.04亿美元，即每股78美分。动视暴雪表示，调整后的收益（不包括股权激励费用和其他项目）从去年同期的每股88美分上涨了89美分。</blockquote></p><p> Revenue rose to $2.07 billion from $1.95 billion in the year-ago quarter, while bookings increased to $1.88 billion from $1.77 billion last year. Bookings represent the value of digital products and services sold during a quarter, but part of the revenue from those purchases is often recognized in future quarters.</p><p><blockquote>收入从去年同期的19.5亿美元增至20.7亿美元，预订量从去年同期的17.7亿美元增至18.8亿美元。预订代表一个季度内销售的数字产品和服务的价值，但这些购买的部分收入通常会在未来几个季度确认。</blockquote></p><p> Analysts surveyed by FactSet had forecast 70 cents a share on revenue of $1.88 billion and bookings of $1.87 billion, based on the company’s forecast of 75 cents a share on revenue of $1.97 billion and bookings of $1.85 billion.</p><p><blockquote>FactSet调查的分析师此前预测每股70美分，营收18.8亿美元，预订量18.7亿美元，而该公司预测每股75美分，营收19.7亿美元，预订量18.5亿美元。</blockquote></p><p> On the conference call, Bobby Kotick, Activision Blizzard’s chief executive, acknowledged the company fired more than 20 employees related to allegations of sexual harassment and discrimination over the past quarter, and that it is waiving arbitration requirements for future claims of harassment and discrimination. Kotick also said the company plans to increase the number of women and non-binary employees by 50% within the next five years, so they comprise about one-third of the workforce.</p><p><blockquote>在电话会议上，动视暴雪首席执行官Bobby Kotick承认，该公司在过去一个季度解雇了20多名与性骚扰和歧视指控有关的员工，并将放弃对未来骚扰和歧视指控的仲裁要求。科蒂克还表示，公司计划在未来五年内将女性和非二元员工的数量增加50%，使她们约占员工总数的三分之一。</blockquote></p><p> “Right now workplace leadership is my focus,” said Bobby Kotick, Activision Blizzard’s chief executive, on the call. “Our opportunities for growth as we’ve talked about have never been better, but we won’t be able to realize all that growth potential without talent. And to retain and attract the talent we need, we obviously have to be recognized as the very best place to work. This means we have to be the best welcoming inclusive environment.”</p><p><blockquote>动视暴雪首席执行官Bobby Kotick在看涨期权上表示：“目前，工作场所领导力是我的重点。”“正如我们所谈到的，我们的增长机会从未如此之好，但如果没有人才，我们将无法实现所有的增长潜力。为了留住和吸引我们需要的人才，我们显然必须被公认为是最好的工作场所。这意味着我们必须成为最受欢迎的包容性环境。”</blockquote></p><p> Kotick also noted a 2020 review of pay equity from an outside firm showed that “women on average earned slightly more than men for comparable work in 2020,” and that Activision Blizzard was committed to equitable pay.</p><p><blockquote>科蒂克还指出，一家外部公司2020年对薪酬公平的审查显示，“2020年，从事可比工作的女性平均收入略高于男性”，动视暴雪致力于实现薪酬公平。</blockquote></p><p> Activision Blizzard publishes such games as “Call of Duty” through its Activision label; “World of Warcraft,” “Overwatch,” and “Diablo” through its Blizzard label, and “Candy Crush” through its King label. Last week, Activision Blizzard announced it had acquired Barcelona-based mobile game developer Digital Legends for an undisclosed price.</p><p><blockquote>动视暴雪通过旗下动视厂牌发行《使命看涨期权》等游戏；《魔兽世界》、《守望先锋》和《暗黑破坏神》通过其暴雪标签，《糖果粉碎》通过其国王标签。上周，动视暴雪宣布以未公开的价格收购了巴塞罗那手机游戏开发商Digital Legends。</blockquote></p><p></p><p> Take-Two Interactive Inc.,Electronic Arts Inc.,and Playtika Holding Corp. are scheduled to report earnings on Wednesday.</p><p><blockquote>Take-Two Interactive Inc.、Electronic Arts Inc.和Playtika Holding Corp.定于周三公布财报。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Activision Blizzard stock dropped 11% in premarket trading<blockquote>动视暴雪股价盘前交易下跌11%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActivision Blizzard stock dropped 11% in premarket trading<blockquote>动视暴雪股价盘前交易下跌11%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-03 16:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Activision Blizzard Inc. shares sank in premarket trading Wednesday after the videogame publisher’s lighter-than-expected outlook and expected delay of two games eclipsed an earnings beat and commitments to a safe and equitable work environment.</p><p><blockquote>动视暴雪公司(Activision Blizzard Inc.)股价周三在盘前交易中下跌，此前这家视频游戏发行商的前景弱于预期，两款游戏的预期延迟盖过了盈利预期以及对安全公平工作环境的承诺。</blockquote></p><p> Activision Blizzard shares sank more than 11% after the earnings call. Shares fell 2.1% to close at $77.67 Tuesday to give Activision Blizzard a $60.4 billion market cap.</p><p><blockquote>财报看涨期权公布后，动视暴雪股价下跌逾11%。周二，动视暴雪股价下跌2.1%，收于77.67美元，市值达到604亿美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/75c797cd99fe04a5d5f5968df8835903\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The company said it expects fourth-quarter adjusted earnings of 62 cents a share on revenue of $2.02 billion and bookings of $2.78 billion. The company also raised its full-year forecast to earnings of $3.70 a share on revenue of $8.66 billion and bookings of $8.65 billion, compared with its quarter-ago forecast of $3.54 a share on revenue of $8.52 billion and bookings of $8.65 billion for the year.</p><p><blockquote>该公司表示，预计第四季度调整后每股收益为62美分，营收为20.2亿美元，预订量为27.8亿美元。该公司还将全年预期上调至每股收益3.70美元，营收86.6亿美元，预订量86.5亿美元，而上一季度预期为每股收益3.54美元，全年营收85.2亿美元，预订量86.5亿美元。</blockquote></p><p> Analysts, however, estimated earnings of $1.38 a share on revenue of $2.91 billion and bookings of $2.89 billion for the fourth quarter, and earnings of $3.83 a share on revenue of $8.79 billion and bookings of $8.76 billion for the year.</p><p><blockquote>然而，分析师预计第四季度每股收益为1.38美元，营收为29.1亿美元，预订量为28.9亿美元，全年每股收益为3.83美元，营收为87.9亿美元，预订量为87.6亿美元。</blockquote></p><p> Activision Blizzard Chief Financial Officer Armin Zerza said on the call “we remain prudent in our revenue assumption for the fourth quarter, and regarding costs we have decided to further step up investment in mobile marketing given the strong returns we are currently seeing and compliance in the organization.”</p><p><blockquote>动视暴雪首席财务官Armin Zerza在看涨期权上表示：“我们对第四季度的收入假设保持谨慎，在成本方面，鉴于我们目前看到的强劲回报和合规性，我们决定进一步加大对移动营销的投资在组织中。”</blockquote></p><p> For the fourth quarter, Activision Blizzard said it will roll out “Call of Duty: Vanguard” on Friday, and the franchise’s “Warzone Pacific” update on Dec. 5. Other anticipated titles, however, are getting delayed.</p><p><blockquote>对于第四季度，动视暴雪表示将于周五推出《使命看涨期权：先锋》，并于12月5日推出该系列的《战区太平洋》更新。然而，其他预期的标题正在被推迟。</blockquote></p><p> “While we are still planning to deliver a substantial amount of content from Blizzard next year, we are now planning for a later launch for ‘Overwatch 2’ and ‘Diablo IV’ than originally envisaged,” Daniel Alegre, the company’s chief operating officer, said on the call. “These are two of the most eagerly anticipated titles in the industry, and our teams have made great strides towards completion in recent quarters.”</p><p><blockquote>该公司首席运营官Daniel Alegre在看涨期权上表示：“虽然我们仍计划明年从暴雪提供大量内容，但我们现在计划推出《守望先锋2》和《暗黑破坏神4》的时间比最初设想的要晚。”“这是业内最受期待的两个游戏，我们的团队最近几个季度在完成方面取得了长足的进步。”</blockquote></p><p> Delays in releases have become more commonplace as publishers seek to avoid releasing games that may still have bugs, especially since CD Projekt SA’s long-awaited and long-overdue release last year of “Cyberpunk 2077” that forced distributors like Sony Group Corp. to offer full refunds.</p><p><blockquote>随着发行商试图避免发布可能仍有漏洞的游戏，发行延迟变得越来越普遍，特别是自CD Projekt SA去年发布期待已久的《赛博朋克2077》以来，该游戏迫使索尼集团公司等发行商提供全额退款。</blockquote></p><p> The company reported third-quarter net income of $639 million, or 82 cents a share, compared with $604 million, or 78 cents a share, in the year-ago period. Activision said adjusted earnings, which exclude share-based compensation expenses and other items, rose 89 cents a share from 88 cents a share in the year-ago period.</p><p><blockquote>该公司报告第三季度净利润为6.39亿美元，即每股82美分，而去年同期为6.04亿美元，即每股78美分。动视暴雪表示，调整后的收益（不包括股权激励费用和其他项目）从去年同期的每股88美分上涨了89美分。</blockquote></p><p> Revenue rose to $2.07 billion from $1.95 billion in the year-ago quarter, while bookings increased to $1.88 billion from $1.77 billion last year. Bookings represent the value of digital products and services sold during a quarter, but part of the revenue from those purchases is often recognized in future quarters.</p><p><blockquote>收入从去年同期的19.5亿美元增至20.7亿美元，预订量从去年同期的17.7亿美元增至18.8亿美元。预订代表一个季度内销售的数字产品和服务的价值，但这些购买的部分收入通常会在未来几个季度确认。</blockquote></p><p> Analysts surveyed by FactSet had forecast 70 cents a share on revenue of $1.88 billion and bookings of $1.87 billion, based on the company’s forecast of 75 cents a share on revenue of $1.97 billion and bookings of $1.85 billion.</p><p><blockquote>FactSet调查的分析师此前预测每股70美分，营收18.8亿美元，预订量18.7亿美元，而该公司预测每股75美分，营收19.7亿美元，预订量18.5亿美元。</blockquote></p><p> On the conference call, Bobby Kotick, Activision Blizzard’s chief executive, acknowledged the company fired more than 20 employees related to allegations of sexual harassment and discrimination over the past quarter, and that it is waiving arbitration requirements for future claims of harassment and discrimination. Kotick also said the company plans to increase the number of women and non-binary employees by 50% within the next five years, so they comprise about one-third of the workforce.</p><p><blockquote>在电话会议上，动视暴雪首席执行官Bobby Kotick承认，该公司在过去一个季度解雇了20多名与性骚扰和歧视指控有关的员工，并将放弃对未来骚扰和歧视指控的仲裁要求。科蒂克还表示，公司计划在未来五年内将女性和非二元员工的数量增加50%，使她们约占员工总数的三分之一。</blockquote></p><p> “Right now workplace leadership is my focus,” said Bobby Kotick, Activision Blizzard’s chief executive, on the call. “Our opportunities for growth as we’ve talked about have never been better, but we won’t be able to realize all that growth potential without talent. And to retain and attract the talent we need, we obviously have to be recognized as the very best place to work. This means we have to be the best welcoming inclusive environment.”</p><p><blockquote>动视暴雪首席执行官Bobby Kotick在看涨期权上表示：“目前，工作场所领导力是我的重点。”“正如我们所谈到的，我们的增长机会从未如此之好，但如果没有人才，我们将无法实现所有的增长潜力。为了留住和吸引我们需要的人才，我们显然必须被公认为是最好的工作场所。这意味着我们必须成为最受欢迎的包容性环境。”</blockquote></p><p> Kotick also noted a 2020 review of pay equity from an outside firm showed that “women on average earned slightly more than men for comparable work in 2020,” and that Activision Blizzard was committed to equitable pay.</p><p><blockquote>科蒂克还指出，一家外部公司2020年对薪酬公平的审查显示，“2020年，从事可比工作的女性平均收入略高于男性”，动视暴雪致力于实现薪酬公平。</blockquote></p><p> Activision Blizzard publishes such games as “Call of Duty” through its Activision label; “World of Warcraft,” “Overwatch,” and “Diablo” through its Blizzard label, and “Candy Crush” through its King label. Last week, Activision Blizzard announced it had acquired Barcelona-based mobile game developer Digital Legends for an undisclosed price.</p><p><blockquote>动视暴雪通过旗下动视厂牌发行《使命看涨期权》等游戏；《魔兽世界》、《守望先锋》和《暗黑破坏神》通过其暴雪标签，《糖果粉碎》通过其国王标签。上周，动视暴雪宣布以未公开的价格收购了巴塞罗那手机游戏开发商Digital Legends。</blockquote></p><p></p><p> Take-Two Interactive Inc.,Electronic Arts Inc.,and Playtika Holding Corp. are scheduled to report earnings on Wednesday.</p><p><blockquote>Take-Two Interactive Inc.、Electronic Arts Inc.和Playtika Holding Corp.定于周三公布财报。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATVI":"动视暴雪"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123197935","content_text":"Activision Blizzard Inc. shares sank in premarket trading Wednesday after the videogame publisher’s lighter-than-expected outlook and expected delay of two games eclipsed an earnings beat and commitments to a safe and equitable work environment.\nActivision Blizzard shares sank more than 11% after the earnings call. Shares fell 2.1% to close at $77.67 Tuesday to give Activision Blizzard a $60.4 billion market cap.\n\nThe company said it expects fourth-quarter adjusted earnings of 62 cents a share on revenue of $2.02 billion and bookings of $2.78 billion. The company also raised its full-year forecast to earnings of $3.70 a share on revenue of $8.66 billion and bookings of $8.65 billion, compared with its quarter-ago forecast of $3.54 a share on revenue of $8.52 billion and bookings of $8.65 billion for the year.\nAnalysts, however, estimated earnings of $1.38 a share on revenue of $2.91 billion and bookings of $2.89 billion for the fourth quarter, and earnings of $3.83 a share on revenue of $8.79 billion and bookings of $8.76 billion for the year.\nActivision Blizzard Chief Financial Officer Armin Zerza said on the call “we remain prudent in our revenue assumption for the fourth quarter, and regarding costs we have decided to further step up investment in mobile marketing given the strong returns we are currently seeing and compliance in the organization.”\nFor the fourth quarter, Activision Blizzard said it will roll out “Call of Duty: Vanguard” on Friday, and the franchise’s “Warzone Pacific” update on Dec. 5. Other anticipated titles, however, are getting delayed.\n“While we are still planning to deliver a substantial amount of content from Blizzard next year, we are now planning for a later launch for ‘Overwatch 2’ and ‘Diablo IV’ than originally envisaged,” Daniel Alegre, the company’s chief operating officer, said on the call. “These are two of the most eagerly anticipated titles in the industry, and our teams have made great strides towards completion in recent quarters.”\nDelays in releases have become more commonplace as publishers seek to avoid releasing games that may still have bugs, especially since CD Projekt SA’s long-awaited and long-overdue release last year of “Cyberpunk 2077” that forced distributors like Sony Group Corp. to offer full refunds.\nThe company reported third-quarter net income of $639 million, or 82 cents a share, compared with $604 million, or 78 cents a share, in the year-ago period. Activision said adjusted earnings, which exclude share-based compensation expenses and other items, rose 89 cents a share from 88 cents a share in the year-ago period.\nRevenue rose to $2.07 billion from $1.95 billion in the year-ago quarter, while bookings increased to $1.88 billion from $1.77 billion last year. Bookings represent the value of digital products and services sold during a quarter, but part of the revenue from those purchases is often recognized in future quarters.\nAnalysts surveyed by FactSet had forecast 70 cents a share on revenue of $1.88 billion and bookings of $1.87 billion, based on the company’s forecast of 75 cents a share on revenue of $1.97 billion and bookings of $1.85 billion.\nOn the conference call, Bobby Kotick, Activision Blizzard’s chief executive, acknowledged the company fired more than 20 employees related to allegations of sexual harassment and discrimination over the past quarter, and that it is waiving arbitration requirements for future claims of harassment and discrimination. Kotick also said the company plans to increase the number of women and non-binary employees by 50% within the next five years, so they comprise about one-third of the workforce.\n“Right now workplace leadership is my focus,” said Bobby Kotick, Activision Blizzard’s chief executive, on the call. “Our opportunities for growth as we’ve talked about have never been better, but we won’t be able to realize all that growth potential without talent. And to retain and attract the talent we need, we obviously have to be recognized as the very best place to work. This means we have to be the best welcoming inclusive environment.”\nKotick also noted a 2020 review of pay equity from an outside firm showed that “women on average earned slightly more than men for comparable work in 2020,” and that Activision Blizzard was committed to equitable pay.\nActivision Blizzard publishes such games as “Call of Duty” through its Activision label; “World of Warcraft,” “Overwatch,” and “Diablo” through its Blizzard label, and “Candy Crush” through its King label. Last week, Activision Blizzard announced it had acquired Barcelona-based mobile game developer Digital Legends for an undisclosed price.\nTake-Two Interactive Inc.,Electronic Arts Inc.,and Playtika Holding Corp. are scheduled to report earnings on Wednesday.","news_type":1,"symbols_score_info":{"ATVI":0.9}},"isVote":1,"tweetType":1,"viewCount":2785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}